tbuckley/cabot-search huggingface dataset:
Abstract 16336: Comprehensive ex vivo Biomechanical Analysis of Five Clinically Utilized Operative Approaches to Reimplantation Aortic Valve-Sparing Root Replacement
Authors: Michael J Paulsen, Annabel Imbrie-Moore, Hanjay Wang, Camille E Hironaka, Haley Lucian, Justin Farry, Akshara Thakore, Peter Chiu, Michael Ma, Y Joseph Woo
Journal: Circulation (2019)

Introduction: Many graft configurations are clinically employed for valve-sparing aortic root replacement (VSRR), but the benefit of neosinus reconstruction remains unclear. Using ex vivo analysis,...
The Use of Microfluidic Platforms to Probe the Mechanism of Cancer Cell Extravasation
Authors: Mark F. Coughlin, Roger D. Kamm
Journal: Advanced Healthcare Materials (2020)

Abstract Powerful experimental tools have contributed a wealth of novel insight into cancer etiology from the organ to the subcellular levels. However, these advances in understanding have outpaced improvements in clinical outcomes. One possible reason for this shortcoming is the reliance on animal models that do not fully replicate human physiology. An alternative in vitro approach that has recently emerged features engineered microfluidic platforms to investigate cancer progression. These devices allow precise control over cellular components, extracellular constituents, and physical forces, while facilitating detailed microscopic analysis of the metastatic process. This review focuses on the recent use of microfluidic platforms to investigate the mechanism of cancer cell extravasation.
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
Authors: H. Pfeifer, G. Cazzaniga, V. H. J. van der Velden, J. M. Cayuela, B. Schäfer, O. Spinelli, S. Akiki, S. Avigad, I. Bendit, K. Borg, H. Cavé, L. Elia, S. C. Reshmi, G. Gerrard, S. Hayette, M. Hermanson, A. Juh, T. Jurcek, M. C. Chillón, C. Homburg, G. Martinelli, V. Kairisto, T. Lange, T. Lion, M. C. Mueller, F. Pane, L. Rai, C. Damm-Welk, T. Sacha, S. Schnittger, T. Touloumenidou, H. Valerhaugen, P. Vandenberghe, J. Zuna, H. Serve, E. Herrmann, S. Markovic, J. J. M. van Dongen, O. G. Ottmann
Journal: Leukemia (2020)
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Authors: John T. Poirier, Julie George, Taofeek K. Owonikoko, Anton Berns, Elisabeth Brambilla, Lauren A. Byers, David Carbone, Huanhuan J. Chen, Camilla L. Christensen, Caroline Dive, Anna F. Farago, Ramaswamy Govindan, Christine Hann, Matthew D. Hellmann, Leora Horn, Jane E. Johnson, Young S. Ju, Sumin Kang, Mark Krasnow, James Lee, Se-Hoon Lee, Jonathan Lehman, Benjamin Lok, Christine Lovly, David MacPherson, David McFadden, John Minna, Matthew Oser, Keunchil Park, Kwon-Sik Park, Yves Pommier, Vito Quaranta, Neal Ready, Julien Sage, Giorgio Scagliotti, Martin L. Sos, Kate D. Sutherland, William D. Travis, Christopher R. Vakoc, Sarah J. Wait, Ignacio Wistuba, Kwok Kin Wong, Hua Zhang, Jillian Daigneault, Jacinta Wiens, Charles M. Rudin, Trudy G. Oliver
Journal: Journal of Thoracic Oncology (2020)
Abstract 11799: Omega-3 Therapy is Associated With Reduced Hemocompatibility-Related Adverse Events Following Left Ventricular Assist Device Implantation
Authors: Teruhiko Imamura, Ann Nguyen, Daniel Rodgers, Gene Kim, Jayant Raikhelkar, Nitasha Sarswat, Sara Kalantari, Bryan Smith, Ben Chung, Nikhil Narang, Colleen Juricek, Tae Song, Takeyoshi Ota, Valluvan Jeevanandam, Gabriel Sayer, Nir Uriel
Journal: Circulation (2018)

Background: Hemocompatibility-related clinical adverse events (HRAEs) are major causes of readmission and reduce quality of life in patients with left ventricular assist devices (LVADs). Omega-3 is...
Randomized Controlled Trial Comparing Health Coach-Delivered Smartphone-Guided Self-Help With Standard Care for Adults With Binge Eating
Authors: Tom Hildebrandt, Andreas Michaeledes, Meghan Mayhew, Rebecca Greif, Robyn Sysko, Tatiana Toro-Ramos, Lynn DeBar
Journal: American Journal of Psychiatry (2020)

Objective: Cognitive-behavioral therapy (CBT) has shown efficacy in the treatment of eating disorders. The authors conducted a randomized controlled telemedicine trial of CBT-guided self-help (CBT-GSH) assisted with a smartphone app, Noom Monitor, for binge eating with or without purging. They hypothesized that coach-delivered CBT-GSH telemedicine sessions plus Noom Monitor would yield greater reductions in symptoms of binge eating, purging, and eating disorders compared with standard care. Methods: Fifty-two-week outcomes for CBT-GSH plus Noom Monitor (N=114) were compared with outcomes for standard care (N=111) among members of an integrated health care system in the Pacific Northwest. Patients in the health system who met inclusion criteria were ≥18 years old, had a body mass index ≥18.5, met criteria for DSM-5 binge eating disorder or bulimia nervosa, had 12 months of continuous health care enrollment in Kaiser Permanente Northwest, and had a personal smartphone. Participants received eight CBT-GSH telemedicine sessions over 12 weeks administered by health coaches, and outcomes were assessed at baseline and at weeks 4, 8, 12, 26, and 52. The use of available treatment offered within the Kaiser Permanente health care system was permitted for participants assigned to standard care. Results: Participants who received CBT-GSH plus Noom Monitor reported significant reductions in objective binge-eating days (β=−0.66, 95% CI=−1.06, −0.25; Cohen’s d=−1.46, 95% CI=−4.63, −1.09) and achieved higher rates of remission (56.7% compared with 30%; number needed to treat=3.74) at 52 weeks compared with participants in standard care, none of whom received any eating disorder treatment during the intervention period (baseline and weeks 1–12). Similar patterns emerged for compensatory behaviors (vomiting, use of laxatives, and excessive exercise; 76.3% compared with 56.8%; number needed to treat=5.11), eating disorder symptoms (body shape, weight, eating concerns, and dietary restraint), and clinical impairment (Cohen’s d=−10.07, −2.15). Conclusions: These results suggest that CBT-GSH plus Noom Monitor delivered via telemedicine by routine-practice health coaches in a nonacademic health care system yields reductions in symptoms and impairment over 52 weeks compared with standard care.
Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study
Authors: Giulia Ferrannini, Maria Laura Manca, Marco Magnoni, Felicita Andreotti, Daniele Andreini, Roberto Latini, Attilio Maseri, Aldo P. Maggioni, Rachel M. Ostroff, Stephen A. Williams, Ele Ferrannini
Journal: Diabetes Care (2020)

OBJECTIVE Coronary artery disease (CAD) is a major challenge in patients with type 2 diabetes (T2D). Coronary computed tomography angiography (CCTA) provides a detailed anatomic map of the coronary circulation. Proteomics are increasingly used to improve diagnostic and therapeutic algorithms. We hypothesized that the protein panel is differentially associated with T2D and CAD. RESEARCH DESIGN AND METHODS In CAPIRE (Coronary Atherosclerosis in Outlier Subjects: Protective and Novel Individual Risk Factors Evaluation—a cohort of 528 individuals with no previous cardiovascular event undergoing CCTA), participants were grouped into CAD− (clean coronaries) and CAD+ (diffuse lumen narrowing or plaques). Plasma proteins were screened by aptamer analysis. Two-way partial least squares was used to simultaneously rank proteins by diabetes status and CAD. RESULTS Though CAD+ was more prevalent among participants with T2D (HbA1c 6.7 ± 1.1%) than those without diabetes (56 vs. 30%, P &amp;lt; 0.0001), CCTA-based atherosclerosis burden did not differ. Of the 20 top-ranking proteins, 15 were associated with both T2D and CAD, and 3 (osteomodulin, cartilage intermediate-layer protein 2, and HTRA1) were selectively associated with T2D only and 2 (epidermal growth factor receptor and contactin-1) with CAD only. Elevated renin and GDF15, and lower adiponectin, were independently associated with both T2D and CAD. In multivariate analysis adjusting for the Framingham risk panel, patients with T2D were “protected” from CAD if female (P = 0.007), younger (P = 0.021), and with lower renin levels (P = 0.02). CONCLUSIONS We concluded that 1) CAD severity and quality do not differ between participants with T2D and without diabetes; 2) renin, GDF15, and adiponectin are shared markers by T2D and CAD; 3) several proteins are specifically associated with T2D or CAD; and 4) in T2D, lower renin levels may protect against CAD.
Precision Microbiome Modulation with Discrete Dietary Fiber Structures Directs Short-Chain Fatty Acid Production
Authors: Edward C. Deehan, Chen Yang, Maria Elisa Perez-Muñoz, Nguyen K. Nguyen, Christopher C. Cheng, Lucila Triador, Zhengxiao Zhang, Jeffrey A. Bakal, Jens Walter
Journal: Cell Host & Microbe (2020)
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
Authors: Yuankai Shi, Shucai Zhang, Xingsheng Hu, Jifeng Feng, Zhiyong Ma, Jianying Zhou, Nong Yang, Lin Wu, Wangjun Liao, Dafang Zhong, Xiaohong Han, Ziping Wang, Xiaodong Zhang, Shukui Qin, Kejing Ying, Jian Feng, Jian Fang, Li Liu, Yong Jiang
Journal: Journal of Thoracic Oncology (2020)

IntroductionAlflutinib (AST2818) is a newly developed third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M-resistant mutations. We assessed the safety, efficacy, and pharmacokinetics of alflutinib in patients with advanced NSCLC with confirmed EGFR T790M mutation, whose status progressed after the first- or second-generation EGFR tyrosine kinase inhibitor therapy.MethodsIn the dose-escalation (NCT02973763) and dose-expansion (NCT03127449) studies, patients received alflutinib orally until disease progression, unacceptable toxicity, or subject withdrawal. The primary end points were safety, tolerability, and pharmacokinetics for the dose-escalation study and the objective response rate (assessed by an independent radiological review committee) for the dose-expansion study.ResultsBetween November 30, 2016, and July 24, 2018, a total of 130 patients (14 in dose escalation, 116 in dose expansion) received alflutinib treatment (20 mg, 40 mg, 80 mg, 160 mg, or 240 mg once daily). On October 30, 2018, 79 patients (61%) remained on the treatment. No dose-limiting toxicities were observed in the dose-escalation study. In the dose-expansion study (40–240 mg), the overall objective response rate was 76.7% (89 of 116), and it was 70.6% in patients with central nervous system metastases (12 of 17). A total of 79% of all patients had possibly treatment-related adverse events (AEs) (103 of 130); 8% had treatment-related grade 3 or higher AEs (11 of 130). Serious AEs were reported in 15% of patients (20 of 130), and two serious AEs were related to treatment. No clear dose-response (antitumor activity and AEs) relationships were observed. Exposures to alflutinib and its active metabolite (AST5902) were comparable at steady state.ConclusionsAlflutinib was clinically effective with an acceptable toxicity profile in patients with advanced NSCLC (including those with central nervous system metastases) with EGFR T790M mutation. Further investigation is ongoing.
Prediabetes in Youth
Authors: Bridget Kuehn
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anhydrous Ammonia Chemical Release — Lake County, Illinois, April 2019
Authors: Jared R. Rispens, Sydney A. Jones, Nakia S. Clemmons, Sana Ahmed, Laurel Harduar-Morano, Mark D. Johnson, Charles Edge, Aditi Vyas, Ellie Bourgikos, Maureen F. Orr
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

On April 25, 2019, a farm tractor towing two 2-ton ammonia tanks on a county road in Lake County, Illinois, experienced a mechanical failure that resulted in the release of anhydrous ammonia, a colorless, pungent, irritating gas that can cause severe respiratory and ocular damage (1). Approximately 80% of anhydrous ammonia produced in the United States is used as a fertilizer in agriculture (1). Eighty-three persons, including first responders, motorists, and neighborhood residents, were evaluated at area hospitals because of exposure to the gas. Two weeks after the release, the Agency for Toxic Substances and Disease Registry (ATSDR) and CDC's National Center for Environmental Health (NCEH) collaborated with the Lake County Health Department and the Illinois Department of Public Health on an investigation using ATSDR's Assessment of Chemical Exposures program to describe the release, review the emergency response, and determine health effects associated with the exposure. First responders, community residents, and hospital personnel reported communication challenges related to the nature of the gas release and effective protective measures. Among the 83 persons evaluated at six area hospitals for effects of the chemical release, 14 (17%) were hospitalized, including eight (10%) who were admitted to the intensive care unit (ICU), seven (8%) of whom required endotracheal intubation and mechanical ventilation; no deaths occurred. In addition, ICU health care providers experienced symptoms of secondary exposure. The National Institute for Occupational Safety and Health's Emergency Responder Health Monitoring and Surveillance Program has specific recommendations and tools to protect responders during all phases of a response (2). Hospitals also need to review institutional policies and procedures for chemical mass casualty events, including decontamination (3). Prompt and correct identification of hazardous material (hazmat) events, and clear communication among responding entities, including on-scene and hospital responders, is important to ensure effective response after a chemical release.
Abstract 10275: The Role and Mechanism of Chronic Ca2+/Calmodulin-Dependent Protein Kinase II Inhibition in a Mouse Model of Diabetic Cardiomyopathy
Authors: Heng-Jie Cheng, Yixi Liu, Xiaoqiang Sun, Jen-Jar Lin, Alexei V Mikhailov, David Zhao, Dalane Kitzman, Che Ping Cheng
Journal: Circulation (2019)

Background: Emergent evidence indicates that CaMKII is upregulated in diabetes and plays an important role in promoting diabetic cardiomyopathy (DCM) by targeting a diverse array of proteins involv...
Transparency in Patient Access to Dermatopathologic Reports
Authors: Daniel Miller
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Six Weeks of Prednisolone Reduced Hand Osteoarthritis Pain
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Authors: Alexander Biederstädt, Zonera Hassan, Christian Schneeweis, Markus Schick, Lara Schneider, Alexander Muckenhuber, Yingfen Hong, Gerrit Siegers, Lisa Nilsson, Matthias Wirth, Zahra Dantes, Katja Steiger, Kathrin Schunck, Steve Langston, H-P Lenhof, Andrea Coluccio, Felix Orben, Jolanta Slawska, Anna Scherger, Dieter Saur, Stefan Müller, Roland Rad, Wilko Weichert, Jonas Nilsson, Maximilian Reichert, Günter Schneider, Ulrich Keller
Journal: Gut (2020)

Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumour biology. It is clear that hyperactivation of MYC generates dependencies that can be exploited therapeutically. The aim of the study was to find and to target MYC-associated dependencies.We analysed human PDAC gene expression datasets. Results were corroborated by the analysis of the small ubiquitin-like modifier (SUMO) pathway in a large PDAC cohort using immunohistochemistry. A SUMO inhibitor was used and characterised using human and murine two-dimensional, organoid and in vivo models of PDAC.We observed that MYC is connected to the SUMOylation machinery in PDAC. Components of the SUMO pathway characterise a PDAC subtype with a dismal prognosis and we provide evidence that hyperactivation of MYC is connected to an increased sensitivity to pharmacological SUMO inhibition.SUMO inhibitor-based therapies should be further developed for an aggressive PDAC subtype.
The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer
Authors: Hong Zhu, Yan Hu, Chenming Zeng, Linlin Chang, Fujin Ge, Weihua Wang, Fangjie Yan, Qinxin Zhao, Ji Cao, Meidan Ying, Yongchuan Gu, Lin Zheng, Qiaojun He, Bo Yang
Journal: Theranostics (2020)

Aldo-keto reductase family 1 member C1 (AKR1C1) promotes malignancy of Non-Small Cell Lung Cancer (NSCLC) by activating Signal Transducer and Activator of Transcription 3 (STAT3) pathway.However, how the pro-metastatic functions of AKR1C1 are switched on/off remains unknown.Methods: Immunoprecipitation and LC-MS/MS analyses were performed to identify the acetylation on AKR1C1 protein, and the functional analyses (in vitro and in vivo) were performed to depict the contribution of acetylation to the pro-metastatic effects of AKR1C1.Results: Here we report that acetylated AKR1C1 on two lysine residues K185 & K201 is critical to its pro-metastatic role.The acetylation modification has no impact on the canonical enzymatic activity of AKR1C1, while it is required for the interaction between AKR1C1 to STAT3, which triggers the downstream transduction events, ultimately mobilizing cells.Importantly, the deacetylase Sirtuin 2 (SIRT2) is capable of deacetylating AKR1C1, inhibiting the transactivation of STAT3 target genes, thus suppressing the migration of cells.Conclusion: Acetylation on Lysines 185 and 201 of AKR1C1 dictates its pro-metastatic potential both in vitro and in vivo, and the reverting of acetylation by Sirtuin 2 provides potential therapeutic targets for treatment against metastatic NSCLC patients with high AKR1C1 expression.